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Abstract
Background: Withaferin A (WA), a naturally occurring withanolide, induces apoptosis in both estrogen-responsive
MCF-7 and estrogen-independent MDA-MB-231 breast cancer cell lines with higher sensitivity in MCF-7 cells, but
the underlying mechanisms are not well defined. The purpose of this study was to determine the anti-cancer
effects of WA in MCF-7 breast cancer cells and explore alterations in estrogen receptor alpha (ERa) and its
associated molecules in vitro as novel mechanisms of WA action.
Methods: The effects of WA on MCF-7 viability and proliferation were evaluated by 3-(4, 5-dimethylthiazol-2-yl)-5-
(3-carboxymethoxyphenyl)-2-(4-sulfophenyl)-2H-tetrazolium (MTS) assay and trypan blue exclusion assays. Apoptosis
was evaluated by Annexin V-fluorescein isothiocyanate (FITC)/propidium iodide (PI) flow cytometry and Western
blot analysis of poly (ADP-ribose) polymerase (PARP) cleavage. Cell cycle effects were analyzed by PI flow
cytometry. Western blotting was also conducted to examine alterations in the expression of ERa and pathways
that are associated with ERa function.
Results: WA resulted in growth inhibition and decreased viability in MCF-7 cells with an IC50 of 576 nM for 72 h. It
also caused a dose- and time-dependent apoptosis and G2/M cell cycle arrest. WA-induced apoptosis was
associated with down-regulation of ERa, REarranged during Transfection (RET) tyrosine kinase, and heat shock
factor-1 (HSF1), as well as up-regulation of phosphorylated p38 mitogen-activated protein kinase (phospho-p38
MAPK), p53 and p21 protein expression. Co-treatment with protein synthesis inhibitor cycloheximide or
proteasome inhibitor MG132 revealed that depletion of ERa by WA is post-translational, due to proteasome-
dependent ERa degradation.
Conclusions: Taken together, down-regulation of ERa, RET, HSF1 and up-regulation of phospho-p38 MAPK, p53,
p21 are involved in the pro-apoptotic and growth-inhibitory effects of WA in MCF-7 breast cancer cells in vitro.
Down-regulation of ERa protein levels by WA is caused by proteasome-dependent ERa degradation.
Background
Breast cancer is the most common cancer and the sec-
ond most common cause of cancer-related death among
women in the United States [1]. This disease is usually
treated through surgery and/or radiotherapy, supported
by adjuvant endocrine or chemo-therapy. Unfortunately,
most tumors acquire resistance during classical
treatments [2]. Therefore, there is a need for developing
novel therapeutics for breast cancer. Approximately 70%
of breast cancers are estrogen receptor alpha (ERa)-
positive [3]. ERa plays an important role in these can-
cers via both ligand-dependent and -independent
mechanisms [4]. ERa is a member of the super family of
nuclear receptors that function as transcription factors.
In addition to estrogen-induced activation, it also inter-
acts with growth factor pathways [5]. The role of ERa
in breast cancer development has been extensively
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cell survival and estrogen-independent growth [6]
whereas ERa knock-down induces cell apoptosis and
growth inhibition [7] in estrogen-responsive MCF-7
breast cancer cells. Recent research also indicates that
estrogen-independent ERa signaling and its interaction
with growth factor receptors contribute to endocrine
resistance in breast cancer treatment [8]. As such, ERa
has become an important target in developing breast
cancer therapies.
Withaferin A (WA) is a steroidal lactone occurring in
Withania somnifera that has shown cytotoxicity in a
variety of tumor cell lines and in animal cancer models
in vivo without any noticeable systemic toxicity [9]. The
mechanism of its action is currently under extensive
investigation. It has been demonstrated that WA has the
ability to alter numerous cancer-associated growth fac-
tor receptors, kinases, and transcription factors. It is a
potent inhibitor of nuclear factor-B activation [10], and
angiogenesis [11]. In prostate cancer cell lines, WA
binds to Heat shock protein 90 (Hsp90) and inhibits its
chaperone activity, resulting in Hsp90 client protein
degradation and tumor inhibition [12]. Recent research
revealed that treatment with WA causes apoptosis and
growth inhibition in both the ERa-negative, p53-mutant
MDA-MB-231 and the ERa-positive, p53-wildtype
MCF-7 breast cancer cell lines, but MCF-7 cells exhibit
higher sensitivity to the apoptotic effect of WA [13,14].
The molecular mechanism underlying the anti-cancer
effects of WA in breast cancer is not well defined.
We hypothesized that ERa and its associated molecu-
lar network such as REarranged during Transfection
(RET) tyrosine kinase and p53 may be involved in the
anti-cancer effects of WA in MCF-7 breast cancer cells.
ERa and the tumor suppressor protein p53 exert oppos-
ing effects on breast cancer cell proliferation and apop-
tosis. ERa promotes proliferation of breast cancer cells
whereas p53 induces growth inhibition and apoptosis
[7]. RET is over-expressed in breast cancer ERa-positive
breast cancer, and its activation stimulates MCF-7 breast
cancer cell proliferation, survival and scattering [5,15].
In the present study, we examined the effects of WA on
MCF-7 cell proliferation, viability, cell cycle distribution,
and apoptosis, and addressed whether ERa and its asso-
ciated molecular network may in part mediate the anti-
cancer effects of WA in MCF-7 breast cancer cells.
Methods
Cell Lines and Reagents
The MCF-7 cells were purchased from the American
Type Culture Collection (ATCC; Manassas, VA) and
cultured in RPMI-1640 containing 10% fetal bovine
serum (FBS), 100 units/Ml penicillin, 100 μg/mL strep-
tomycin, 100 μg/mL gentamycin, 2 mM glutamine, and
1 mM pyruvate. The WA was purchased from Chroma-
Dex (Irvine, CA). The antibodies against p53, RET, p21,
poly(ADP-ribose) polymeras e( P A R P ) ,c a s p a s e - 3 ,c a s -
pase-7, p38 mitogen-activated protein kinase (p38
MAPK), phospho-p38 MAPK, heat shock factor 1
(HSF1) were purchased from Cell Signaling Technology
(Danvers, MA) and the antibodies against ERa and sur-
vivin were purchased from Santa Cruz Biotechnology
(Santa Cruz, CA). The anti-b-actin antibody was from
Millipore (Billerica, MA). The anti-annexin V-fluores-
cein isothiocyanate (FITC)-conjugated and propidium
iodide (PI) were from BD Bioscience (Rockville, MD).
MTS assay
The effects of WA on MCF-7 cell viability was exam-
ined using 3-(4, 5-dimethylthiazol-2-yl)-5-(3-carboxy-
methoxyphenyl)-2-(4-sulfophenyl)-2H-tetrazolium
(MTS) assay as previously described with minor modifi-
cation [16]. Cells were seeded in 96-well microtiter
plates (1.0 × 10
3 per well) in 100 μLo fg r o w t hm e d i a .
Cells were allowed to attach overnight and then treated
with increasing concentrations of WA (0, 0.156, 0.313,
0.625, 1.25, 2.5, 5 μM) for 72 h. Cisplatin was used as a
positive control. 20 μL of MTS solution was added at 72
h of treatment. After 3 h of incubation at 37°C (5%
CO2), absorbance was measured at 490 nm with a
microplate reader. The half-maximal inhibitory concen-
tration (IC50) was obtained from the MTS viability
curves using GraphPad Prism 5. Experiments were car-
ried out in triplicates and the viability was expressed as
the ratio of the number of viable cells with WA treat-
ment to that without treatment. Experiments were
repeated and similar results were obtained.
Trypan Blue Exclusion Assay
Cell proliferation was evaluated using trypan blue exclu-
sion assay as described before [17] with minor modifica-
tion. MCF-7 cells were plated into 6-well plates at 20,
000 cells/well. After an overnight incubation, cells were
treated with the vehicle (0.125% DMSO) or different
doses of WA (0, 0.5, 1, and 2.5 μM) for 24 h. Cells
exposed to 0.2% Trypan blue were then counted in a
hemocytometer, and cells stained with Trypan blue were
excluded. Percentage of viable cells was calculated based
on the ratio of viable cell to total cell population in each
well. The proliferation rate was calculated based on the
number of viable cells in WA-treated group versus vehi-
cle-treated group. Experiments were repeated to confirm
the accuracy of the results.
Annexin V-FITC/PI Flow Cytometry
The effects of WA on MCF-7 cell apoptosis was exam-
ine using annexin V-fluorescein isothiocyanate (FITC)/
propidium iodide (PI) flow cytometry as described
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WA for 24 h or with 2.5 μM of WA for 0, 6, 12 and 24
h. Detached and adherent cells were then collected and
labeled for 15 min at room temperature with annexin
V-FITC (1 μg/mL) and with PI (40 μg/mL) and immedi-
ately analyzed on a BD™LSRII flow cytometer (BD
Biosciences) using BD FACSDiva6.0 software.
Cell Cycle Analysis
The effects of WA on cell cycle distribution was exam-
ined using PI flow cytometry as described before [16]
with minor modification. MCF-7 cells were seeded in
complete medium (2 × 10
5 per 100-mm plate). After an
overnight incubation, cells were treated with 0, 0.5, 1,
2.5 μMo fW Af o r2 4ho rw i t h2 . 5μM of WA for 0, 6,
12 and 24 h. Detached and adherent cells were collected
and fixed in 70% ethanol in phosphate-buffered saline
( P B S )a t- 2 0 ° Co v e r n i g h t .C e lls were then resuspended
in PBS containing 40 μg/mL PI and 100 μg/mL RNAse
and incubated for 30 min at 37°C in the dark. Samples
were then analyzed on a on a BD™LSRII flow cytometer
(BD Biosciences) using BD FACSDiva6.0 software.
Western Analysis
M C F - 7c e l l sw e r et r e a t e dw i t h0 ,0 . 5 ,1 ,2 . 5 ,5μMo f
WA for 24 h or with 2.5 μM of WA for 0, 1, 3, 6, 12,
24 and 48 h. Detached and adherent cells were col-
lected, and total proteins were extracted using radioim-
muno-precipitation assay buffer (RIPA buffer; 20 mM
Tris [pH 7.5], 150 mM NaCl, 1% IGEPAL CA-630, 0.5%
sodium deoxycholate, 1 mM ethylenediaminetetra-acetic
acid, and 0.1% SDS) containing a protease/phosphatase
inhibitor cocktail (0.1 mg/ml PMSF, 30 μl/ml of aproti-
nin, 5 μg/ml of leupeptin, and 1 mM sodium orthovana-
date; Sigma). Protein concentrations were determined
using the BCA protein assay reagent kit (Pierce, Rock-
ford, IL). Equal amount of proteins were subjected to
SDS-polyacrylamide gel electrophoresis (PAGE) and
electroblotted onto nitrocellulose membranes (Hybond;
Amersham, Piscataway, NJ). After blocking with 3%
nonfat dry milk in PBS for 1 h at room temperature,
blots were incubated with appropriate primary antibo-
dies overnight at 4°C. Blots were then washed and incu-
bated with appropriate horseradish peroxidase (HRP)-
conjugated secondary antibodies for 1 h and protein
b a n d sw e r ev i s u a l i z e du s i n gac h e m i l u m i n e s c e n c ek i t
(Thermo Scientific, Rockford, IL). Next, blots were
stripped and reprobed for b-actin. The expression level
of each protein was normalized to the level of b-actin.
In order to examine whether WA down-regulates ERa
protein at post-translational level, we treated MCF-7
cells with 100 μg/ml of protein synthesis inhibitor cyclo-
heximide in the absence or presence of 2.5 μMW Af o r
1, 2, 4, or 6 h. Cells were collected at each time points
and total proteins were isolated and subjected to Wes-
tern analysis for ERa and b-actin.
To examine whether proteasomal degradation of ERa
is involved in ERa protein down-regulation by WA,
MCF-7 cells were pre-treated with 30 μM of proteasome
inhibitor MG132 for 1 h before treatment with 2.5 μM
WA for 6 h. Cells were then collected and proteins in
triton-soluble or triton-insoluble fractions were isolated
as described previously [18]. Briefly, cells were washed
w i t hP B Sa n dl y s e di nR I P Ab u f f e rf o r1 0m i no ni c e .
After the cell suspensions were centrifuged at 16, 000 ×
g for 15 min at 4°C, the supernatants were collected as
the Triton-soluble fraction. The pellet (Triton-insoluble
fraction) was lysed in 2% SDS in 50 mM Tris-HCl and
boiled for 15 min. The protein concentration of each
sample was determined using the BCA protein assay.
Samples were subjected to Western analysis for ERa
and b-actin.
Statistical Analysis
All data were analyzed using SPSS Version 17.0 software
(SPSS, Inc.). ANOVA was used for comparison across
treatment regimes. When an F test indicated statistical
significance, post hoc analysis was made using the
Tukey’s honestly significant difference procedure. Signif-
icance was set at P < 0.05 for all comparisons.
Results
WA causes growth inhibition in MCF-7 cells
The growth-inhibitory effect of WA on MCF-7 cells was
demonstrated by MTS assay (Figure 1) and trypan blue
exclusion assay (Figure 2). As shown in Figure 1, treat-
ments with WA for 72 h at concentrations between 313
nM and 5 μM reduced the number of viable cells. 50%
Figure 1 Effect of WA on MCF-7 cell viability as measured by
MTS assay. Cells (1 × 10
3 per well) were cultured in 96-well plates
for 24 h, and treated with indicated concentrations of WA for 72 h.
The viable cells were quantified by MTS assay in triplicates.
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WA at 72 h. Similarly, Trypan blue exclusion assay
showed that WA significantly decreased the number of
viable MCF-7 cells at 24 h after treatment in a dose-
dependent manner. WA decreased the percentage of
viable cells in total cell population to 50% at between 1
to 2.5 μM, and decreased the number of viable cells to
50% compared to controls at between 0.5 to 1 μM.
WA induces cell cycle arrest in MCF-7 cells
To examine whether the growth inhibitory effect of WA
on MCF-7 cells was partly due to cell cycle arrest, we
performed cell cycle analysis using PI staining. MCF-7
cells were treated with 0, 0.5, 1 and 2.5 μMo fW Af o r
2 4ho rw i t h2 . 5μM of WA for 0, 6, 12 and 24 h. As
shown in Figure 3, treatment with WA induced G2/M
cell cycle arrest in MCF-7 cells in a dose- and time-
dependent manner. Interestingly, WA induced a
decrease in G0/G1 fractions and an increase in G2/M
fractions at 24 h, which were most evident with 0.5 μM
of WA and gradually subsided with increasing doses. In
the 2.5 μM WA time course study, the cells showed
transient G2/M cell cycle arrest at 12 h. By 24 h, the
percentage of cells in G2/M phase returned to control
levels.
WA induces apoptosis in MCF-7 cells
To address whether WA causes apoptosis, we first did
Annexin V-FITC/PI flow cytometry. As shown in Figure
4, WA significantly induces apoptosis in a dose- and
time-dependent manner. In the dose response study,
MCF-7 cells were treated with 0, 1, 2.5 and 5 μMo f
WA for 24 h. Early apoptosis (defined as Annexin V-
positive/PI-negative) was induced by 1 μMW Aa t2 4h
(12.7% increase compared to controls). 2.5 μMo fW A
induced more late apoptosis (23.5%) than early apoptosis
(4.6%), while 5 μM of WA mainly induced late apoptosis
(67.4%). In the time course study, cells were treated with
2.5 μM of WA for 0, 6, 12 and 24 h. No significant
increase in apoptosis could be seen at 6 h. At 12 and 24
h, increase in both early apoptosis (3.3% and 3.4%,
respectively,) and late apoptosis (13.9% and 29.5%,
respectively) was induced. The WA-induced apoptosis
in MCF-7 cells was also confirmed by Western analysis
of PARP cleavage as well as caspase-3 and caspase-7
activation (Figure 5A and 5B). In the dose response
study, 2.5 or 5 μM of WA significantly increased PARP
cleavage at 24 h, which is associated with a decrease in
pro-caspase3 and pro-caspase7 levels. In the time course
study, slight but significant increase in PARP cleavage
could be seen at 12 h after treatment with 2.5 μMo f
WA. By 24 h, PARP cleavage became more apparent.
WA regulates ERa and its associated signaling pathways
To examine the molecular pathways underlying the anti-
proliferative and pro-apoptotic effects of WA, we exam-
ined ERa protein levels and its associated signaling
pathways by Western analysis (Figure 5A). WA mark-
edly decreased ERa protein levels in a dose- and time-
dependent manner. ERa protein levels diminished at 24
h after treatment with 2.5 or 5 μM of WA. The decrease
in ERa occurred as early as 3 h post WA treatment
(Figure 5B). We then examined the protein expression
of RET kinase, which is over-expressed in a subset of
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Figure 2 Effect of WA on MCF-7 cell proliferation as measured by Trypan blue exclusion assay. Cells were treated with DMSO or the
indicated concentrations of WA for 24 h. A, percentage of viable cells in total cell population; B, the number of viable cells. Data were presented
as mean (n = 3) ± SD. *, P < 0.05, significantly different from control by one-way ANOVA.
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Page 4 of 10ERa-positive breast cancers and is a novel proliferative
pathway interacting with ERa signaling in MCF-7 breast
cancer cells [5]. We found that WA caused a marked
decrease in RET protein expression in parallel with ERa
down-regulation.
Since ERa counteracts the action of the tumor sup-
presser p53, which is another major regulator of MCF-7
cell proliferation and survival, we next examined the
effects of WA on p53 protein expression. We found that
p53 was up-regulated by WA in MCF-7 cells, starting at
3 h and reaching maximum increase between 6 to 12 h
post-treatment with 2.5 μM of WA. As p21 is a key
inhibitor of cell cycle progression in MCF-7 cells, and is
often stimulated by p53 [19], we analyzed the expression
of p21 protein and correlated it with that of p53. We
found that p21 expression was markedly up-regulated
by WA as compared to controls, with kinetics closely
following p53 expression (Figure 5B).
Survivin, a member of the inhibitors of apoptosis
family, is a critical regulator of proliferation [20].
Because p53 is a known repressor of survivin expression
and ERa inhibits this effect of p53, we decided to exam-
ine survivin expression after WA treatment in MCF-7
cells. Intriguingly, survivin protein expression was mark-
edly decreased at 24 h after treatments with 2.5 or 5
μM of WA, while WA at 0.5 or 1 μM slightly increased
survivin protein levels, suggesting other pathways that
may control survivin expression. Since an earlier study
reported that knockdown of HSF1 leads to a decrease of
survivin expression [21], we examined the effect of WA
on HSF1 protein expression. Interestingly, 2.5 or 5 μM
of WA markedly decreased HSF1 expression at 24 h,
while an additional band of HSF1 with slower mobility
showed up after treatments with 0.5 or 1 μM of WA for
24 h, which likely indicates phosphorylation/activation
of HSF1 (Figure 5A). The expression patterns of HSF1
and survivin appeared to correlate with each other.
We also examined the effect of WA on the expression
and phosphorylation of the pro-apoptotic p-38 MAPK.
We found that 2.5 μM of WA did not affect the levels
of total p-38 MAPK protein expression within 3 h, but
gradually decreased it after 6 h. In contrast, phospho-
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Figure 3 Effect of WA on MCF-7 cell cycle distribution as measured by propidium iodide flow cytometry. A and C, cells were treated
with DMSO or the indicated concentrations of WA for 24 h. B and D, cells were treated with 2.5 μM WA for indicated time periods. Results were
presented as mean (n = 3) ± SD. *, P < 0.05, significantly different from control by one-way ANOVA.
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Page 5 of 10p38 MAPK was transiently increased by WA at 1 h and
3 h post treatment.
To elucidate the mechanism of ERa protein down-
regulation, protein synthesis inhibitor cycloheximide or
proteasome inhibitor MG132 was used together with
WA. We found that ERa protein levels became mark-
edly lower at 2 h after treatment with cycloheximide
plus WA as compared to cycloheximide alone, and even
lower by 4 or 6 h (Figure 6A), indicating that WA post-
translationally down-regulates ERa protein levels. In
cells treated with MG231 and WA, the ERa protein was
lost from Triton-insoluble fraction and accumulated in
the Triton-insoluble fraction (Figure 6B), indicating that
WA caused ERa protein aggregation and then induced
proteasome-dependent ERa protein degradation.
Discussion
In this study, we aimed to examine the anti-cancer
effects of WA in ERa-positive MCF-7 breast cancer
cells and explore the role of ERa and pathways asso-
ciated with it in mediating these effects. We found that
WA has potent inhibitory effects on the protein expres-
sion of ERa as well as RET tyrosine kinase that interacts
with ERa pathway. WA also strongly up-regulated the
protein levels of p53 and its down-stream target p21.
Furthermore, WA at 2.5 or 5 μM markedly decreased
HSF1 and survivin protein levels. These molecular
changes correlate well with WA-induced dose- and
time-dependent alterations in cell viability and apopto-
sis, suggesting that these are key factors involved in the
anti-cancer effects of WA.
5 μM WA 2.5 μM WA 1 μM WA 0 μM WA
A
B
0 h 6 h 12 h 24 h
0
10
20
30
40
50
60
70
80
90
0 1 2.5 5
P
e
r
c
e
n
t
a
g
e
 
o
f
 
c
e
l
l
s
WA (μM)
Early Apoptosis
Late Apoptosis
0
5
10
15
20
25
30
35
40
0 6 12 24
P
e
r
c
e
n
t
a
g
e
 
o
f
 
c
e
l
l
s
Time (hours)
Early Apoptosis
Late Apoptosis
C D
*
*
*
*
*
*
*
*
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and higher levels estrogen are linked to increased risk of
breast cancer [22]. ERa is a transcription factor that
plays a key role in mediating estrogen signaling. Recent
research revealed that ERa also plays a critical role in
breast cancer progression via estrogen-independent
mechanisms [23]. Knockdown of ERa expression using
siRNA for ERa has been found to inhibit cell prolifera-
tion and induce apoptosis in MCF-7 breast cancer cells
[7]. As such, ERa has become a molecular target in the
development of therapeutics for breast cancer. In this
study, WA treatment caused drastic decrease in ERa
protein levels, which most likely contributed to growth
inhibition and apoptosis.
RET is a receptor tyrosine kinase that mediates the
proliferative and pro-survival effects of GDNF family
growth factors in breast cancer. It is over-expressed in
breast cancer, with higher levels in ERa-positive tumors
as compared to ERa-negative tumors. Activation of RET
stimulates MCF-7 breast cancer cell proliferation, survi-
val and scattering [5,15]. RET pathway functionally
interacts with ERa pathway [5]. In the present study, we
found that WA down-regulates RET protein levels in
parallel with ERa depletion. Down-regulation of both
ERa and RET pathways may thus provide more effective
anti-tumor activity.
The tumor suppressor p53 exerts its anti-proliferative
action by inducing reversible or irreversible cell cycle
arrest or apoptosis [24]. P53 can block cell cycle pro-
gression and/or induce apoptosis by transactivation of
specific target genes, including p21Waf-1/Cip1 (p21),
Gadd45, cyclin G and Bax [25,26]. Loss of p53 activity
inhibits apoptosis and accelerates the appearance of
tumors in transgenic mice [27]. The p53 gene is
mutated in approximately 20% of breast cancers. Thus,
although the majority of breast cancers have wild-type
p53, its anti-cancer function remains suppressed. Addi-
tionally, p21 is a critical cell cycle inhibitor in many
cancer cells including MCF-7 cells [28]. It has been
found to be essential for G2/M cell cycle arrest upon
DNA damage [29]. Although its role in apoptosis is con-
troversial in general, it has been reported to induce
apoptosis in MCF-7 cells [19,30]. In the present study,
we found that WA increased the protein levels of p53
and p21, suggesting that they are involved in the growth
inhibition and pro-apoptotic effects of WA. The pattern
of p21 correlated well with that of p53, indicating that
p 5 3m a yp l a yar o l ei np 2 1u p - r e g u l a t i o nb yW A .A n
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Figure 5 Effect of WA on MCF-7 cell protein expression as measured by Western analysis. A, Western analysis of the expression of ERa,
RET, p53, p21, HSF-1, survivin, PARP, pro-caspase3, pro-caspase7 at 24 h after treatments with increasing concentrations of WA in MCF-7 cells. B,
Western analysis of the expression of p38, phospho-p38, ERa, RET, p53, p21, HSF-1, survivin, PARP, pro-caspase3, pro-caspase7 at 0, 1, 3, 6, 12, 24,
and 48 h after treatment with 2.5 μM of WA in MCF-7 cells.
Zhang et al. BMC Complementary and Alternative Medicine 2011, 11:84
http://www.biomedcentral.com/1472-6882/11/84
Page 7 of 10up-regulation of phospho-p38 MAKP was observed at 1
h and 3 h post WA treatment, preceding the up-regula-
tion of p53. Since phopho-p38 MAPK has been demon-
strated to up-regulate p53 expression [31], and WA is
able to induce apoptosis by activating p38 in leukemic
cells [32], it appears that the p38 pathway may be an
up-stream pathway involved in the anti-cancer effects of
WA in MCF-7 cells.
Accumulating evidence indicates that there is a cross-
talk between pathways mediated by ERa and p53. ERa
and p53 exert opposing effects on breast cancer cell
proliferation [7]. ERa binds directly to p53, leading to
down-regulation of transcriptional activation or depres-
sion by p53. For example, wild-type p53 can be func-
tionally inhibited by ERa leading to up-regulation of
survivin and suppression of apoptosis [7]. RNA interfer-
ence-mediated knockdown of ERa insulted in reduced
survivin expression and enhanced apoptosis in MCF-7
breast cancer cells [7]. The depletion of ERa in combi-
nation with the up-regulation of p53 following WA
treatment in MCF-7 cells mayr e n d e rt h ec e l l sm o r e
sensitive to apoptosis. The fact that WA can also induce
apoptosis, although not as effective, in MDA-MB-231
breast cancer cell line [[14], and unpublished data from
our lab] which is ERa negative and p53-mutant, sug-
gests that WA targets multiple pathways in its anti-can-
cer function, and neither ERa nor wild-type p53 is
indispensable for the anti-cancer effect of WA. However,
it is reasonable to postulate that in ERa-positive and
p53-wild-type breast cancer cells, depletion of ERa and
up-regulation of p53 substantially contribute to the anti-
cancer effects of WA.
HSF1, the transcription factor for heat shock proteins
(HSP), has recently been shown as a facilitator of trans-
formation in breast cancer [33,21]. HSF1 inactivation
inhibits the progression of a wide spectrum of cancers
ERα
β-actin
1 h            2 h           4 h          6h  A
B
ERα
β-actin
Triton-soluble
Triton-soluble
ERα
β-actin
Triton-insoluble
Triton-insoluble
Figure 6 WA down-regulates ERa expression at post-translational level by inducing proteasomal degradation of ERa protein.A ,
Western analysis of the expression of ERa after treatment with 100 μg/ml cychloheximide (Chx) in the absence or presence of 2.5 μM WA for 1,
2, 4, or 6 h. B, Western analysis of the expression of ERa after treatment with 30 μM MG132 (MG) for 1 h followed by 2.5 μM WA for 6 h.
Proteins from both triton-soluble and triton-insoluble fractions were examined.
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HSF1 is also a target in designing anti-breast cancer
therapies. HSF1 is another up-stream regulator of survi-
vin. Down-regulation of HSF1 leads to decreased survi-
vin expression in breast cancer cells [21]. In the present
study, 2.5 or 5 μM of WA markedly decreased HSF1
and survivin expression at 24 h, suggesting that HSF1
may play a role in WA-induced apoptosis in part by reg-
ulating survivin expression. At lower concentrations or
early time points, WA induced HSF1 phosphorylation,
which is likely due to a transient defensive response of
cells to the stress caused by WA.
In this study, WA induction of apoptosis in MCF-7
cells was confirmed by Annexin V assay as well as
PARP cleavage and decreased expression of the pro-cas-
pase3 and pro-caspase7. The amount of pro-caspase7 is
much more abundant as compared to pro-caspase3 in
MCF-7 cells, and this is in agreement with earlier
reports [36]. At 1 μM, WA induced mainly early apop-
tosis. At higher concentrations (2.5 and 5 μM), the
number of early apoptotic cells decreased whereas more
late apoptotic cells were detected. It appears that
whether it is early apoptosis or late apoptosis primarily
depends on the concentration of WA, as mainly late
apoptosis was detected with 2.5 μMW Aa t1 2hw h e n
apoptosis became detectable. WA causes minimal necro-
sis in MCF-7 cells. The small number of cells gated to
the necrosis fraction after treatment with WA is most
likely artifact caused by trypsinization, because when we
tried Annexin V experiments at 36 h after 2.5 μMW A
treatment without trypsinization (cells were all detached
by 36 h), nearly 100% of cells were gated to the last
apoptosis fraction (data not shown).
A recently published paper by Hahm et al. [37] also
reported down-regulation of ERa and up-regulation of
p53. However, they declared that WA-mediated decline
in ERa protein level is caused by transcriptional repres-
sion, instead of proteasomal degradation. Our data
showed that WA decreased ERa at post-translational
level by inducing aggregation and proteasome-depen-
dent degradation of ERa protein. The reason why they
failed to see any effect of MG132 on WA-induced
decline in ERa protein level is most likely that they only
examined ERa p r o t e i ni nT r i t o n - s o l u b l ef r a c t i o nb u t
not in Triton-insoluble fraction.
Conclusions
In summary, we report here that WA induces apoptosis
and growth inhibition in MCF-7 breast cancer cells at
least in part through down-regulation of ERa,R E T ,
HSF-1, as well as up-regulation of p53 and p21. WA
depletes ERa levels by inducing proteasomal degrada-
tion of ERa protein. These findings help to explain the
mechanisms underlying the anti-cancer effect of WA in
ERa-positive, p53-wild type breast cancer, and reveals
WA as a promising agent in breast cancer therapy.
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